Since EGFR is shown to be highly expressed in tumor-associated endothelial cells, and both secreted and cellular hRNase5/ANG can be detected in endothelial cells [48, 190], it is possible that, similar to the findings in pancreatic cancer, secretory hRNase5/ANG from tumor-associated endothelial cells may bind to EGFR on the endothelial cell surface, leading to the activation of EGFR signaling in an autocrine manner. The gene discussed is ANG; the disease is neoplasm.